Member Info for banner76

Ok to disagree, as I understand it BP has delayed or postponed any listing on US stock markets. I would imagine BP management have a reason for this, lack of demand from investors is probably the most logical explanation.

I see several posters trying to compare BP with PATH. You have think through why PATH is so highly rated and why BP is not. These are different companies selling different products into the same market, BP is falling behind as it's product is poor compared to PATHs offering. This is how the market works the weak are cast aside whilst the strong grow stronger, hence the difference in share price and ratings

Cannot really see this share going anywhere soon, ok for for day traders to hopefully make a profit on price swings but as a long term investment its a no.

Thompi you were correct in that assumption. I consider POLX to be a worthwhile investment given the current environment.

So apart from two share spikes in the past 5 years why is this share attractive to buy, apart from you already have a holding and wanting to push the price up?

Telegraph states this a speculative buy, much depends on FDA approval latter this year. However there is a convincing story to be told here given the COVID pandemic, I would suggest a large buy into these shares then closely monitor events given the significant upside.

By the way Rich if you had followed by advice on Friday and purchased TGR you would have made a 40% profit on that investment. In that post I mentioned in Gartmore,one of my old employers.

Additionally, I would say a company that has seen a 40% decline in the value of its share price over the past two years and just issued a profits warning should be treated with extreme caution.

You don't seem to be able to read very well, I said I had experience of fund management industry yet you to equate that to me claiming to be expert fund manager. An inability understand basic English would indicate that any investment advice you may have to offer to be of little value. My experience in the fund management industry is related to my time at Schroders, Gartmore and Henderson, if you have questions relating those companies feel free to ask.

My experience in fund management is that profit warnings rarely occur as singular events. It's a question of do trust the management of the company to deliver on the promises and forecasts they have made given the current and possible future environment. Personally speaking I can't see them being able to deliver on those promises, of course if have more detailed information I would've delighted to hear it.

I am pleased you are making a profit on these shares, but your statements regarding COB and beyond that are at best flimsy. Anyone good luck for CLIN, but I am out of this one.

If you can see into the future then you shouldn't be on on here wasting your time. It's a very high risk buy, my guess is your post is 50% emotion and 50% hope. Chances of substantial upward movement of the share price, based on any available evidence in the public domain, are miniscule.

About every technical measure you could possibly think of, but I am not your PA so do your own research

Another old stock market saying for you, as mentioned in the article, profit warnings come in threes. One down two to go.

Old stock market saying, never try to catch a falling knife. CLIN is a falling knife. High risk buy

And furthermore, if you were a successful investor you wouldn't be wasting your time on here.

I gave you my thoughts, it's up to you to ever accept or reject them. I suggest you keep you childish thoughts to yourself.

Then you should invest everything you have into PRSM. I spoke to someone involved in RPA for a large financial services company and my comment about the future was based on their reply. A speculative buy at very best, but today we should see some uplift.

Given the article in the Sunday Telegraph I would expect price gains tomorrow, however the future for Blue Prism is a minefield. As a long term investment its about as high risk as high risk can be, the big tech firms with huge budgets will simply out muscle the smaller companies on price

I knew Gervais Williams at Gartmore, a very clever and intelligent fund manager. If he says buy then this share is a buy, in fact fill your boots.